Daiichi Sankyo (United Kingdom)

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

Harry P. Erba, Pau Montesinos, Hee‐Je Kim et al. · The Lancet · 2023 · 319 citations

Hematological Malignancy, Medicine, Hematology +5

Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline

Börje Darpö, T Nebout, Philip T. Sager · The Journal of Clinical Pharmacology · 2006 · 316 citations

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz et al. · The Lancet · 2016 · 243 citations

Thrombosis, Cardiovascular Disease, Pharmacology +8

Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-<i>ras</i> gene than in control non-transgenic mice

Satoshi Yamamoto, Kunitoshi Mitsumori, Yukio Kodama et al. · Carcinogenesis · 1996 · 133 citations · Full text

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen et al. · Annals of the Rheumatic Diseases · 2019 · 131 citations · Full text